Key Highlights
- Roche Holding AG reported positive phase 3 results for sefaxersen in IgA nephropathy.
- The drug is partnered with Ionis Pharmaceuticals, Inc. and was tested in the IMAGINATION study.
- Roche's Jay Garg, global head of nephrology, rheumatology, and cardiovascular, said the result should hopefully lead to accelerated approval.
- The drug sets up direct competition with Novartis AG's already-approved therapy Fabhalta.
A Positive Result From the IMAGINATION Study
Roche Holding AG reported positive phase 3 results for sefaxersen, formerly known as IONIS-FB-LRx, in patients with IgA nephropathy, a kidney disease, from the company's IMAGINATION study conducted in Partnership with Ionis Pharmaceuticals, Inc.. Jay Garg, M.D., Roche's global head of nephrology, rheumatology, and cardiovascular, said the results should hopefully lead to accelerated approval, signaling the company's confidence in the strength of the phase 3 data package.
Meaningful Commercial Expectations
Roche's head of investor relations, Bruno Eschli, noted that the drug is included in most analyst models with roughly EUR 400 million, or about USD 457 million, in forecasted 2030 sales, giving investors a concrete sense of the commercial expectations already embedded in market models for sefaxersen even ahead of formal approval. Expectations of this kind, already built into analyst models before regulatory approval, suggest the market has been anticipating positive phase 3 results for some time.
A Direct Competitive Matchup With Fabhalta
Sefaxersen's positive results set up direct competition with Novartis AG's Fabhalta, an oral, twice-daily therapy that also targets complement Factor B and won accelerated FDA approval in IgA nephropathy in 2024 before receiving full approval in 2025. A key differentiator cited in coverage is that sefaxersen, administered as a monthly subcutaneous injection, reportedly does not show the cholesterol side effect observed with Fabhalta, a distinction that could influence physician and patient treatment preferences between the two competing therapies.
Where Things Stand
Roche's positive phase 3 results for sefaxersen in IgA nephropathy, backed by Jay Garg's confidence in a path toward accelerated approval, sets up a direct competitive matchup against Novartis' established Fabhalta in the kidney-disease treatment space. The reported absence of the cholesterol side effect seen with Fabhalta could prove an important differentiator as both companies compete for share in this therapeutic area.






Please wait processing your request...